This clearance enables the initiation of the clinical trial addressing this significant target at the medical center within a month. The intended product, primarily for the oncology market, is expected to leverage a formulation of Anadis’s immune milk-derived anti LPS antibodies, growth factors and other bioactives combined and delivered using Anadis’s patented oral delivery technology.
Anadis anticipates a commercial product could reach the market within two-three years, due to the product’s safety profile.